Wu, Yang & Wang
FULL PAPER
dibenzo[d,f][1,3]dioxepines, which are expected to be
promising starting materials to be converted to the re-
lated analogues of 1,3-benzodioxole-containing com-
pounds for their biological studies.
26.6. HRMS (ESI) calcd for C20H15BrO2 366.0255,
found 366.0252 ([M]+).
6-(4-Chlorophenyl)-6-methyldibenzo[d,f][1,3]-
dioxepine 1H NMR (CDCl3, 400 MHz) δ: 7.61 (m,
2H), 7.50 (m, 2H), 7.33 (m, 2H), 7.26 (m, 4H), 6.95 (m,
2H), 1.90 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 151.4,
140.0, 134.1, 133.2, 128.7, 128.2, 128.1, 127.6, 125.3,
123.4, 115.4, 26.7. HRMS (ESI) calcd for C20H15ClO2
322.0761, found 322.0762 ([M]+).
6-(4-Methoxyphenyl)-6-methyldibenzo[d,f][1,3]-
dioxepine17b 1H NMR (CDCl3, 400 MHz) δ: 7.57 (d,
J=8.8 Hz, 2H), 7.50 (t, J=9.3 Hz, 2H), 7.24 (t, J=9.4
Hz, 4H), 6.95 (t, J=9.2 Hz, 2H), 6.86 (d, J=8.6 Hz,
2H), 3.78 (s, 3H), 1.92 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ: 159.4, 151.7, 133.7, 133.3, 128.5, 128.1, 127.3,
125.1, 123.5, 116.0, 113.1, 55.2, 26.7.
6-(Biphenyl-4-yl)-6-methyldibenzo[d,f][1,3]dioxe-
pine 1H NMR (CDCl3, 400 MHz) δ: 7.80 (d, J=8.1
Hz, 2H), 7.65 (t, J=13.2 Hz, 4H), 7.24 (t, J=8.8 Hz,
2H), 7.47 (t, J=14.8 Hz, 2H), 7.38 (t, J=14.7 Hz, 1H),
7.31—7.26 (m, 4H), 7.07 (t, J=8.9 Hz, 2H), 2.01 (s,
3H); 13C NMR (CDCl3, 100 MHz) δ: 151.7, 140.9,
140.6, 140.4, 133.3, 128.7, 128.6, 128.2, 127.4, 127.1,
126.6, 126.5, 125.2, 123.5, 115.9, 26.9. HRMS (ESI)
calcd for C26H20O2 364.1463, found 364.1466 ([M]+).
6-(2-Bromophenyl)-6-methyldibenzo[d,f][1,3]di-
oxepine 1H NMR (CDCl3, 400 MHz) δ: 7.83 (dd, J=
7.9, 1.9 Hz, 1H), 7.71 (dd, J=7.8, 1.3 Hz, 1H), 7.54—
7.49 (m, 2H), 7.29—7.25 (m, 5H), 7.21—7.14 (m, 4H),
2.11 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 151.6,
139.6, 135.0, 133.3, 129.7, 129.5, 128.7, 128.0, 127.2,
125.3, 123.1, 120.7, 115.1, 24.6. HRMS (ESI) calcd for
C20H15BrO2 366.0255, found 366.0261 ([M]+).
Experimental
Physical measurements and materials
All 1H NMR and 13C NMR spectra were recorded on
a 400 MHz Bruker FT-NMR spectrometers. All chemi-
cal shifts are given as δ value with reference to tetrame-
thylsilane (TMS) as an internal standard. Products were
purified by flash chromatography on 230—400 mesh
silica gel, SiO2.
The chemicals and solvents were purchased from
commercial suppliers either from Aldrich, Fluka, USA
or Shanghai Chemical Company, China and were used
without purification prior to use.
Typical procedure for the synthesis of dibenzo[d,f]-
[1,3]dioxepines
To a solution of 2,2'-dihydroxybiphenyl (0.5 mmol)
and phenylacetylene (1.0 mmol) in ClCH2CH2Cl (2.0
mL) was added TiCl4 (0.05 mmol) in one portion. The
reaction mixture was heated to 80 ℃ for 1 h with stir-
ring under a nitrogen atmosphere. After cooling, the
reaction mixture was extracted with ethyl acetate and
the organic layer was dried over Na2SO4. Then, the or-
ganic solution was concentrated with a rotary evaporator,
and the residue was purified by column chromatography
on silica gel using cyclohexane/ethyl acetate (15∶1) as
eluent to provide pure 6-methyl-6-phenyldibenzo[d,f]-
[1,3]dioxepine in 80 % yield.
6-Methyl-6-phenyldibenzo[d,f][1,3]dioxepine17b
1H NMR (CDCl3, 400 MHz) δ: 7.69 (d, J=6.6 Hz, 2H),
7.53—7.51 (m, 2H), 7.40—7.33 (m, 3H), 7.28—7.24 (m,
5H), 7.00—6.98 (m, 2H), 1.94 (s, 3H); 13C NMR
(CDCl3, 100 MHz) δ: 151.7, 141.4, 133.3, 128.6, 128.3,
128.2, 127.9, 126.0, 125.2, 123.5, 115.9, 26.8.
6-(4-tert-Butylphenyl)-6-methyldibenzo[d,f][1,3]-
dioxepine 1H NMR (CDCl3, 400 MHz) δ: 7.59 (d,
J=8.4 Hz, 2H), 7.50—7.48 (m, 2H), 7.36 (d, J=8.4 Hz,
2H), 7.24—7.20 (m, 4H), 7.01—6.97 (m, 2H), 1.90 (s,
3H), 1.31 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 151.8,
151.0, 138.4, 133.3, 128.5, 128.1, 125.6, 125.1, 124.8,
123.6, 116.1, 34.5, 31.3, 27.0. HRMS (ESI) calcd for
C24H24O2 344.1776, found 344.1775 ([M]+).
6-(4-Fluorophenyl)-6-methyldibenzo[d,f][1,3]di-
oxepine17b 1H NMR (CDCl3, 400 MHz) δ: 7.67—7.61
(m, 2H), 7.52—7.49 (m, 2H), 7.27—7.23 (m, 4H), 7.05—
7.00 (m, 2H), 6.96—6.92 (m, 2H), 1.91 (s, 3H); 13C NMR
(CDCl3, 100 MHz) δ: 162.6 (d, JC-F=245.2 Hz), 151.5,
137.3 (d, JC-F=3.1 Hz), 133.2, 128.6, 128.2, 128.0 (d,
JC-F=8.2 Hz), 125.3, 123.4, 115.5, 114.7 (d, JC-F=21.3
Hz), 26.8. HRMS (ESI) calcd for C20H15FO2 306.1056,
found 306.1052 ([M]+).
6-Methyl-6-m-tolyldibenzo[d,f][1,3]dioxepine17b
1H NMR (CDCl3, 400 MHz) δ: 7.57—7.22 (m, 4H),
7.09—6.97 (m, 8H), 2.26 (s, 3H), 1.94 (s, 3H); 13C
NMR (CDCl3, 100 MHz) δ: 151.6, 141.0, 138.1, 133.3,
130.0, 129.2, 128.6, 128.2, 127.4, 123.1, 120.8, 116.1,
106.3, 26.9, 21.4.
6-Methyl-6-p-tolyldibenzo[d,f][1,3]dioxepine17b
1H NMR (CDCl3, 400 MHz) δ: 7.55 (d, J=8.3 Hz, 2H),
7.49 (q, J=9.4 Hz, 2H), 7.25—7.20 (m, 4H), 7.15 (d, J=
8.1 Hz, 2H), 2.33 (s, 3H), 1.91 (s, 3H); 13C NMR
(CDCl3, 100 MHz) δ: 151.7, 138.4, 137.8, 133.3, 128.6,
128.5, 128.1, 125.9, 125.1, 123.5, 116.1, 26.9, 21.1.
6-(4-Bromophenyl)-6-methyldibenzo[d,f][1,3]-
dioxepine 1H NMR (CDCl3, 400 MHz) δ: 7.54—7.45
(m, 6H), 7.24—7.22 (m, 4H), 6.95—6.93 (m, 2H), 1.88 (s,
3H); 13C NMR (CDCl3, 100 MHz) δ: 151.3, 140.4, 133.1,
131.0, 128.6, 128.2, 127.8, 125.3, 123.3, 122.3, 115.3,
6-Methyl-6-o-tolyldibenzo[d,f][1,3]dioxepine17b
1H NMR (CDCl3, 400 MHz) δ: 7.62—7.37 (m, 4H),
7.21—6.75 (m, 8H), 2.31 (s, 3H), 1.90 (s, 3H); 13C
NMR (CDCl3, 100 MHz) δ: 151.6, 142.2, 134.5, 131.3,
130.6, 128.2, 128.2, 127.5, 127.0, 125.6, 120.2, 116.1,
103.6, 27.3, 19.1.
References
1
Dean, F. M. Naturally Occurring Oxygen Ring Compounds,
1214
© 2011 SIOC, CAS, Shanghai, & WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Chin. J. Chem. 2011, 29, 1211— 1215